Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2 clinical study of HLX79 injection in combination with HANLIKANG, a Wednesday Hong Kong bourse filing said.
The study aims to test the drug in this combination for the treatment of active glomerulonephritis in Mainland China, a Wednesday Hong Kong bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.